- Bullfrog AI CEO Vin Singh stated that the agreement the company struck is a validation of its capabilities.
- He remains confident that Bullfrog’s relationship with the pharmaceutical company will expand to other areas of its research and development portfolio.
- Bullfrog uses AI with its bfLEAP, bfPREP, and bfARENAS platforms to provide developers with a path to discover and characterize drug targets for diseases like major depressive disorder.
Bullfrog AI Holdings Inc. (BFRG) shares gained more than 152% in Monday’s opening trade after the company announced a deal with a major global pharmaceutical giant.
Bullfrog AI stated that its agreement requires the company to use its bfLEAP program to identify and prioritize novel drug targets in major depressive disorder (MDD). The company stated that this is aimed at accelerating its drug discovery and clinical development programs.
Retail sentiment on Stocktwits around Bullfrog AI trended in the ‘extremely bullish’ territory with message volumes at ‘high’ levels at the time of writing.
Agreement Is A Validation Of Bullfrog’s Capabilities, Says CEO
Bullfrog AI CEO Vin Singh stated that the agreement the company struck is a validation of its capabilities.
“Our bfLEAP, bfPREP, and bfARENAS integrated platform leverages causal network inference to provide drug developers a clearer path forward in the discovery and characterization of drug targets for a complex disease like MDD,” Singh added. He remains confident that Bullfrog’s relationship with the pharmaceutical company will expand to other areas of its research and development portfolio.
MDD is a mental health condition that is characterized by a loss of interest in activities or persistent and intense sadness. It is also called clinical or unipolar depression.
The company stated that data from Stellar Market Research shows that the MDD market was valued at more than $8 billion in 2025 and is expected to reach $11 billion by 2032.
What Does Bullfrog AI Do?
Bullfrog AI is a Gaithersburg, Maryland-based company that uses artificial intelligence and machine learning to advance drug discovery and development.
The company stated that it uses AI in combination with its bfLEAP platform to analyze complex biological data, aiming to accelerate drug development and reduce clinical trial failure rates.
BFRG stock is up 31% year-to-date, but down 32% over the past 12 months. The Vanguard Total Stock Market Index Fund ETF (VTI) is up 15% over the past 12 months, while the Vanguard Extended Market Index Fund ETF (VXF) is up 16%.
For updates and corrections, email newsroom[at]stocktwits[dot]com.